Upsher-Smith launches TosymraTosymra is the third product in Upsher-Smith's migraine portfolio. Celltrion to launch HIV treatment Temixys Temixys, which the Food and Drug Administration approved last November, is indicated as a single-tablet regimen to treat HIV in combination with other antiretroval agents. Novo Nordisk gets FDA blessing for Rybelsus Novo Nordisk’s Rybelsus is the first GLP-1 analog treatment available in a pill for adults with Type 2 diabetes. Bavarian Nordic gets FDA nod for Jynneos vaccine Bavarian Nordic's Jynneos, is the first live, non-replicating vaccine to prevent smallpox and monkeypox. Ardelyx gets FDA green light for Ibsrela Ardelyx's Ibsrela is a twice-daily oral pill for IBS-C in adults. FDA approves new indication for Eli Lilly’s Taltz The FDA has approved the third indication for Eli Lilly's Taltz. AbbVie gets FDA nod for Rinvoq AbbVie's Rinvoq has the potential to help people living with rheumatoid arthritis achieve remission, AbbVie said. Celgene gets FDA OK for Inrebic Celgene's Inrebic is a new treatment option that may be used in patients with myelofibrosis, including patients previously treated with ruxolitinib. Alfasigma USA reintroduces Zelnorm Alfasigma USA is reintroducing Zelnorm for IBS-C after it was voluntarily withdrawn from the market in 2007. Harmony Biosciences gets FDA nod for Wakix Wakix is the first and only non-scheduled treatment approved for patients with narcolepsy that is not scheduled as a controlled substance by the Drug Enforcement Administration, the company said. First Previous 35 36 37 38 39 Next Last
